Search Results
Dec 10, 2025, 10:11 ET Menarini Group、2025年サンアントニオ乳がんシンポジウムにてエラセストラント（ORSERDU®）併用療法の第2相データをER+、HER2-転移性乳がん（mBC）患者を対象に発表
Groupの完全子会社であるStemline Therapeutics, Inc.（以下「Stemline」）は、コマーシャル・ステージにあるバイオ医薬品会社で、患者に革新的な癌治療を提供することに注力しています。Stemlineは、エストロゲン受容体（ER）陽性、ヒト上皮成長因子受容体2（HER2）陰性、ESR1遺伝子変異の進行・転移性乳がんで、少なくとも1ライン以上の内分泌療法後に病勢進行した閉経後女性または成人男性の治療を適応症とする経口内分泌療法剤エラセストラントを、米国、欧州をはじめとする世界各地で販売しています。また、Stemlineは、CD123に対する新規標的治療薬であるタグラクソフスプ・エルツを、
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 10, 2025, 09:00 ET Cyberpunk 2077 Chromes Up: VITURE x CD PROJEKT RED Unleash the First-Ever Official Limited Edition XR Glasses
and its two expansions. CD PROJEKT RED also created the award-winning Netflix anime series Cyberpunk: Edgerunners, set in the same universe as the game. Together with GOG, a game store offering hand-picked titles for PC and Mac, CD PROJEKT RED is part of the CD PROJEKT Group. CD PROJEKT S.A. is listed
More news about: VITURE
Dec 10, 2025, 09:00 ET Cycode Named a Leader across Innovation and Growth in the 2025 Frost Radar™ for Application Security Posture Management
Report:Unified Visibility: Comprehensive coverage securing code (SAST, SCA, IaC, Container), secrets, and the software supply chain (CI/CD security, runtime eBPF CIMON, code leak detection) in a single platform.AI-Driven Remediation: Emphasis on automation through AI-generated
More news about: Cycode
Dec 10, 2025, 08:32 ET LA RICERCA DI FONDAZIONE TELETHON SBARCA IN USA: VIA LIBERA DALLA FDA ALLA TERAPIA GENICA PER LA SINDROME DI WISKOTT-ALDRICH (WAS)
sindrome di Wiskott-AldrichWaskyra consiste in una singola somministrazione di cellule staminali e progenitrici ematopoietiche autologhe CD34+, trasdotte con un vettore lentivirale che codifica per il gene WAS. Una volta corrette, le cellule staminali vengono reinfuse nel paziente, che viene
More news about: Fondazione Telethon
Dec 10, 2025, 08:00 ET Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
reprogramming of CTCs toward less aggressive phenotypes, confirmed through digital pathology and Nanostring profiling.Significant reduction of exhausted CD8 T cells, with revitalization of cytotoxic and antigen-presentation pathways.CT imaging has demonstrated overall primary tumor volume reduction
More news about: Kazia Therapeutics Limited
Dec 10, 2025, 07:17 ET Fondazione Telethon Announces FDA approval of Waskyra™ (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
risks.About Waskyra™ (etuvetidigene autotemcel) gene therapy for Wiskott-Aldrich syndromeWaskyra consists of a single administration of autologous CD34+ hematopoietic stem and progenitor cells that have been transduced with a lentiviral vector encoding the WAS gene.Once corrected, the stem
More news about: Fondazione Telethon
Dec 10, 2025, 07:12 ET Fondazione Telethon Announces FDA approval of Waskyra™ (etuvetidigene autotemcel), a Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
autotemcel) gene therapy for Wiskott-Aldrich syndromeWaskyra consists of a single administration of autologous CD34+ hematopoietic stem and progenitor cells that have been transduced with a lentiviral vector encoding the WAS gene.Once corrected, the stem
More news about: Fondazione Telethon
Dec 10, 2025, 06:32 ET Herbalife India Launches New Episode of Its Flagship Podcast Featuring Paralympian Palak Kohli Live Your Best Life, Unscripted: A Story of Grit, Purpose & Sporting Excellence
https://music.amazon.com/podcasts/a53233b6-84b5-43ce-a34a-5230c769168b/episodes/660ab985-6b0b-47e0-b0af-cd9e5ef498fc/live-your-best-life-unscripted-the-power-within-building-mental-resilience-for-success-ft-palak-kohli-live-your-best-life-unscriptedHerbalife (NYSE:
More news about: Herbalife India
Dec 09, 2025, 23:19 ET Il Gruppo Menarini presenta i dati di fase 2 sulla combinazione di elacestrant (ORSERDU®) in pazienti affetti da carcinoma mammario metastatico (mBC) ER+, HER2- al Simposio sul cancro al seno di San Antonio del 2025
endocrina, negli Stati Uniti, in Europa e in altre regioni del mondo. Stemline commercializza anche tagraxofusp-erzs, una nuova terapia mirata contro CD123, per i pazienti affetti da neoplasia a cellule dendritiche plasmacitoidi blastiche (BPDCN), un tumore ematologico aggressivo, negli Stati Uniti, in
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 14:24 ET Menarini Group 於 2025 年聖安東尼奧乳癌研討會公佈 Elacestrant (ORSERDU®) 針對 ER+、HER2- 轉移性乳癌 (mBC) 患者的第 2 期聯合治療數據
elacestrant。這是一種口服內分泌藥物，用於治療雌激素受體 (ER) 陽性、第二型人類表皮生長因子受體 (HER2) 陰性、ESR1 突變晚期或轉移性乳癌的已停經女性或成年男性，並接受最少一種內分泌療法後，病情出現惡化。Stemline 也於美國、歐洲和全球其他地區，商業化針對 CD123 的新型標靶藥物 tagraxofusp-erzs。這藥物用於治療母細胞性漿細胞樣樹突狀細胞腫瘤 (BPDCN)，即侵襲性血液癌症。此外，Stemline 於歐洲商業化 selinexor，這是治療多發性骨髓瘤的 XPO1抑制劑。該公司還就乳癌和血液系統癌症適應症，分別利用 elacestrant
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 13:09 ET Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026
Medical CenterABOUT SPEVATAMIGSpevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the
More news about: Phanes Therapeutics, Inc.
Dec 09, 2025, 11:57 ET Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
lifespan. The presentations will showcase both clinical outcomes and manufacturing advances, including enhanced mobilization techniques for the autologous CD34+ hematopoietic stem cells that are base-edited to increase fetal hemoglobin production."Approximately eight million people worldwide live with
More news about: Equity Insider
Dec 09, 2025, 11:38 ET El Grupo Menarini presenta datos de la combinación de fase 2 de Elacestrant (ORSERDU®) en cáncer de mama
terapia endocrina, en Estados Unidos, Europa y otras regiones del mundo. Stemline también comercializa tagraxofusp-erzs, una novedosa terapia dirigida a CD123, para pacientes con neoplasia blástica de células dendríticas plasmocitoides (BPDCN), un cáncer hematológico agresivo, en Estados Unidos, Europa y otras
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 09:49 ET 메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 ER+, HER2- 전이성 유방암(mBC) 환자 대상 2상 병용 요법 데이터 발표
유방암을 앓는 폐경 후 여성 또는 성인 남성 치료제로 지정된 경구용 내분비 요법제인 엘라세스트란트(elacestrant)를 미국, 유럽 및 기타 글로벌 지역에 판매하고 있다. 또한 모구 형질세포양 수지상세포 종양(BPDCN)이라는 공격적 혈액암 환자를 대상으로 하는 CD123 표적 치료제인 tagaxofusp-erzs를 미국, 유럽 및 기타 지역에서 상용화하고 있으며, 다발골수종 치료를 위한 selinexor(XPO1 억제제)도 유럽에서 판매하고 있다. 아울러 유방암 및 혈액암 적응증에서 각각 elacestrant 및 tagraxofusp의
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 09, 2025, 08:00 ET Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR T
SynKIR™-310, a CD19-targeting KIR-CAR T cell therapy, at the American Society of Hematology (ASH) Annual Meeting 2025. The presentation highlights key findings demonstrating that SynKIR™-310 achieved earlier tumor regression with deeper anti-tumor control and reduced cytokine levels compared to CD19-targeting
More news about: Verismo Therapeutics
Dec 09, 2025, 08:00 ET Kosli Launches Spaces to Solve Data Navigation Challenges in Enterprise Software Delivery Governance
financial institutions as they attempt to fully automate software delivery governance. Ingesting large amounts of data from hundreds of sources - CI/CD pipelines, security scanners, test frameworks, deployment tools - means that it becomes increasingly difficult for different stakeholders to access the
More news about: Kosli AS
Dec 09, 2025, 07:44 ET Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.This
More news about: Johnson & Johnson
Dec 09, 2025, 07:30 ET Tec-Dara Combination Offers Substantial Improvement Over Standard Second-Line Therapies for Relapsed or Refractory Multiple Myeloma
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies
More news about: American Society of Hematology
Dec 08, 2025, 15:17 ET Le groupe Menarini présente les données de la phase 2 sur l'association d'Elacestrant (ORSERDU®) chez des patientes atteintes d'un cancer du sein métastatique (mBC) ER+, HER2- lors du 2025 San Antonio Breast Cancer Symposium
Stemline commercialise également aux États-Unis, en Europe et dans d'autres régions du monde le tagraxofusp-erzs, une nouvelle thérapie ciblée sur le CD123, pour les patients atteints de néoplasme blastique des cellules dendritiques plasmacytoïdes (BPDCN), un cancer hématologique agressif. En outre, Stemline
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 14:47 ET Menarini Group präsentiert Daten zur Phase-2-Kombination von Elacestrant (ORSERDU®) bei Patientinnen mit ER+, HER2- metastasiertem Brustkrebs (mBC) auf dem San Antonio Breast Cancer Symposium 2025
endokriner Therapie in den USA, Europa und anderen globalen Regionen angezeigt ist. Stemline vermarktet auch Tagraxofusp-erzs, eine neuartige, gegen CD123 gerichtete Therapie für Patienten mit blastischen plasmazytoiden dendritischen Zellneoplasien (BPDCN), einer aggressiven hämatologischen Krebserkrankung,
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:41 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 13:30 ET Menarini Group Presents Elacestrant (ORSERDU®) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global
More news about: Menarini Industrie Farmaceutiche Riunite
Dec 08, 2025, 12:00 ET Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
NPM1 mutations.5,7 Enzomenib reduced the expression of the leukemia-associated genes HOXA9 and MEIS1 and increased the expression of the differentiation gene CD11b in human acute leukemia cell lines with KMT2A rearrangements and NPM1 mutation.8,9 The safety and efficacy of enzomenib is currently
More news about: Sumitomo Pharma America
Dec 08, 2025, 10:33 ET Halper Sadeh LLC Encourages TRUE, SEE, BLFY Shareholders to Contact the Firm to Discuss Their Rights
to learn more about your legal rights and options.Sealed Air Corporation (NYSE: SEE)'s sale to funds affiliated with CD&R for $42.15 in cash per share. If you are a Sealed Air shareholder,
More news about: Halper Sadeh LLP
Dec 08, 2025, 08:00 ET Ouro Medicines Receives U.S. FDA Orphan Drug Designation for Gamgertamig (OM336) for Immune Thrombocytopenia
periods of relief and avoid the challenges of treatment with immunosuppressive therapies.With a CD3-targeting arm engineered for the reduced induction of T cell cytokines, referred to as a 'detuned' CD3-targeting arm, gamgertamig is designed to avoid severe immune activation while retaining potency
More news about: Ouro Medicines